Webcast – CHMP rekommenderar att Oncopeptides Pepaxti får ett fullt godkännande i EU
June 23, 2022
On June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.
Conference call for investors, analysts, and media
Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022. The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor.
Webcast
The webcast was recorded and can be seen via https://tv.streamfabriken.com/2022-pressconference.